Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
327 Views
eMediNexus 20 October 2020
SGLT2 inhibitors trials
The cardiorenal protection
Independent of glucose-lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors to avoid interfering with the glucose reducing medications taken by a patient.
EMPA-REG Outcome trial 2015
Empagliflozin significantly lowered the risk for cardiovascular death and all-cause mortality in adults with type 2 diabetes and established history of cardiovascular disease.
CANVAS program 2017
Patients with type 2 diabetes at elevated risk for cardiovascular ailment assigned to canagliflozin saw a 33% reduction in the risk ofhospitalization for heart failure and were 40% less likely to experience renal decline versus those assigned placebos.
DECLARE-TIMI 58 trial 2018
Dapagliflozin in patients with type 2 diabetes mellitus, compared with placebo led to a significant 17% renal risk reduction in co-primary efficacy endpoint of a composite of cardiovascular death or hospitalization for heart failure.
CREDENCE trial 2019
Canagliflozin safely decreased the risk of kidney failure and prevented cardiovascular events in patients with type 2 diabetes and chronic kidney disease.
DAPA-HF trial
In heart failure patients, with or without diabetes, treatment with SGLT2 inhibitors reduced the risk for worsening heart failure and cardiovascular death when added to standard therapy;
Guidelines
European Society of Cardiology
Recommends SGLT2 inhibitors to lower the risk of hospitalization for heart failure in patients with type 2 diabetes mellitus.
American Diabetes Association
Advises SGLT2 inhibitors in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease (ASCVD), multiple ASCVD risk factors or diabetic kidney disease to lessen the risk for major adverse events and heart failure hospitalization.
Interdisciplinary communication is needed
References
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}